Rhythms of Change: A Mixtape for Health Equity

 

In today’s healthcare landscape, the focus on health equity signifies a collective awakening to the needs of historically underserved communities. Amidst this backdrop, a pertinent conversation unfolds about how to tailor and scale culturally competent care to address the disparities in health outcomes. Recent studies suggest marginalized groups face a multitude of barriers to quality healthcare compared with more affluent demographics.

What innovative strategies are emerging to tackle the challenges of health equity?

Dr. Nazlim Hagmann, the Chief Medical Officer at Commonwealth Care Alliance, and Lindsay Jubelt, the Chief Population Health Officer at Mass General Brigham, Join Healthcare Rethink host Brian Urban for an insider’s look into transformative initiatives shaking the foundations of traditional healthcare delivery. The conversation examines integrative care models, proactive community engagement, and leveraging technology to bridge care gaps.

Main Points of Discussion:

  • The significance of patient-centered technology in reducing health disparities
  • The burgeoning role of telehealth and AI in managing care for complex populations
  • Strategies for addressing social determinants of health through innovative healthcare partnerships

Dr. Nazlim Hagmann, featured in this episode, brings a rich tapestry of experiences ranging from clinical psychiatry to healthcare administration, underlined by her commitment to whole-person care. Lindsay Jubelt, through her role at Mass General Brigham, stands at the confluence of healthcare innovation and community engagement, seeking to amplify the impact of integrative health strategies.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…